



25th Jan 2019

The Secretary,
Bombay Stock Exchange Limited
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai - 400 001.

The Secretary,
The National Stock Exchange of India
Limited, Exchange Plaza,
Bandra-Kurla Complex, Bandra (E),
Mumbai 400 051

BSE Scrip Code No.524280

NSE Symbol : KOPRAN

Re : US FDA inspection

Dear Sir,

Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, The Active Pharmaceutical Ingredients Manufacturing facility at Madad of Kopran Research Laboratories Ltd., a 100 percent subsidiary of Kopran Ltd. has been inspected by the USFDA starting 21st January till 25th January 2019.

The Inspection has been completed without issuance of any observation under 483. This will facilitate commencement of supplies of APIs to the US market once DMF's are filed and approved. The company has filed the DMF of Atenolol which is already reviewed and active

Regards,

For Kopran Limited

Sunil Sedhani

Company Secretary & Compliance Officer



KOPRAN LTD.: Parijat House, 1076, Dr. E. Moses Road, Worli, Mumbai - 400 018. P.B.No. 9917, Tel.: (022) 4366 1111
Fax : (022) 2495 0363 Website: www.kopran.com • CIN - L 24230 MH 1958 PLC 011078.

Works : • Village Savroli, Taluka : Khalapur, District : Raigad - 410 202. Tel.: (02192) 274500 / 335 / 337 • Fax : (02192) 274025.